In addition, ROS-responsive nanoparticles loaded with elesclomol and copper ions can serve as a targeted drug delivery system, enabling specific release of the drugs at SLC31A1 highly expressed tumor sites. The gene discussed is SLC31A1; the disease is neoplasm.